Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EBT (2016 - 2025)

Historic EBT for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $43.4 million.

  • Collegium Pharmaceutical's EBT rose 17879.33% to $43.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.9 million, marking a year-over-year decrease of 3683.88%. This contributed to the annual value of $98.6 million for FY2024, which is 3015.2% up from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's EBT is $43.4 million, which was up 17879.33% from $17.0 million recorded in Q2 2025.
  • Collegium Pharmaceutical's EBT's 5-year high stood at $46.7 million during Q4 2023, with a 5-year trough of -$38.9 million in Q4 2021.
  • For the 5-year period, Collegium Pharmaceutical's EBT averaged around $10.8 million, with its median value being $15.5 million (2021).
  • Within the past 5 years, the most significant YoY rise in Collegium Pharmaceutical's EBT was 333866.67% (2021), while the steepest drop was 63533.46% (2021).
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's EBT stood at -$38.9 million in 2021, then skyrocketed by 79.96% to -$7.8 million in 2022, then skyrocketed by 699.54% to $46.7 million in 2023, then tumbled by 63.03% to $17.3 million in 2024, then skyrocketed by 151.53% to $43.4 million in 2025.
  • Its EBT stands at $43.4 million for Q3 2025, versus $17.0 million for Q2 2025 and $3.1 million for Q1 2025.